Skip to content
Journal article

Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.

Current opinion in investigational drugs (London, England : 2000), vol. 7, issue 10 (2006) pp. 924-935

  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.
  • N/A


    ScienceDirect users who have downloaded this article.
Sign in to save reference


Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.

Find this document


  • Mary Courtney Moore

Cite this document

Choose a citation style from the tabs below